BioMarin faces challenge from generic rare disease treatment
September 25, 2014 at 21:02 PM EDT
BioMarin Pharmaceutical Inc. is facing a generic challenger to its rare disease drug Kuvan, which since its approval seven years ago has rung up sales of more than $700 million...
